Verrucarin E is a mycotoxin produced by the fungus Myrothecium verrucaria. It has been shown to exhibit a range of biological activities, including cytotoxic, antifungal, and immunosuppressive effects. Verrucarin E has been studied extensively for its potential therapeutic applications, particularly in the treatment of cancer. Its cytotoxic effects are attributed to its ability to inhibit protein synthesis and induce apoptosis in cancer cells. Due to its potent biological activities, Verrucarin E has also been investigated for its potential use in the development of novel antifungal and immunosuppressive drugs. The synthesis of verrucarin E is a complex process involving multiple steps and is typically carried out using chemical methods. The compound is of significant interest to researchers due to its potent biological activities and its potential for therapeutic applications.'
ID Source | ID |
---|---|
PubMed CID | 100243 |
CHEMBL ID | 1966107 |
MeSH ID | M0058863 |
Synonym |
---|
24445-13-4 |
4-acetyl-3-hydroxymethylpyrrole |
nsc-270675 |
ethanone, 1-[4-(hydroxymethyl)-1h-pyrrol-3-yl]- |
nsc270675 |
NCI60_002213 |
verrucarin e |
1-[4-(hydroxymethyl)-1h-pyrrol-3-yl]ethanone |
AKOS006347276 |
ethanone, 1-(4-(hydroxymethyl)-1h-pyrrol-3-yl)- |
unii-m8m1g6524e |
m8m1g6524e , |
1-(4-(hydroxymethyl)-1h-pyrrol-3-yl)ethanone |
nsc 270675 |
CHEMBL1966107 |
DTXSID00179205 |
Q27283654 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (66.67) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |